ArticleInternational journal of hematology2006
Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical hematology.
Article in International journal of hematology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma.Cancer science · 2013Trial
- Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.International journal of hematology · 2007Trial
- Bortezomib induces Rho-dependent hyperpermeability of endothelial cells synergistically with inflammatory mediators.BMC pulmonary medicine · 2024Article
- Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients.International journal of hematology · 2020Article
- Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report.BMC pulmonary medicine · 2020Article
- Bortezomib induced pulmonary toxicity: a case report and review of the literature.American journal of blood research · 2020Article
- Bortezomib-induced diffuse alveolar hemorrhage in a patient with plasma cell leukemia.Respiratory medicine case reports · 2020Article
- Bortezomib-Induced Pulmonary Toxicity: A Case Report and Review of Literature.Case reports in medicine · 2018Article
- Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma.OncoTargets and therapy · 2018Article
- Modified bortezomib, adriamycin and dexamethasone (PAD) regimen in advanced multiple myeloma.Pathology oncology research : POR · 2014Article
- Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization.Cancer science · 2014Article
- Current status of DILD in molecular targeted therapies.International journal of clinical oncology · 2012Review
- Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings.International journal of clinical oncology · 2012Review
- Bortezomib-induced bronchiolitis obliterans organizing pneumonia.Case reports in pulmonology · 2012Article
- Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report.Gut and liver · 2010Article
- Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka.International journal of hematology · 2010Article
- Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma.The Korean journal of hematology · 2010Article
- A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.International journal of hematology · 2009Article
- Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report.Cases journal · 2009Article
- Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma.International journal of hematology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bortezomib is a proteasome inhibitor that can be effective in the treatment of refractory and relapsed multiple myeloma. Recently, severe pulmonary complications associated with bortezomib therapy have been reported in Japan. Because bortezomib has not yet been approved for general use in Japan and is imported by attending physicians on the request of patients, The Japanese Society of Hematology and The Japanese Society of Clinical Hematology sent urgent questionnaires to the councilors of both societies to explore the situation and the details of pulmonary complications associated with bortezomib therapy. Clinical details were available for 46 patients who had been treated with personally imported bortezomib in Japan. Seven patients (15.2%), including 3 who died from respiratory failure, showed complications definitely or probably caused by bortezomib. Of the 7 patients, 6 had a prior history of stem cell transplantation (SCT), whereas only 14 of 39 patients without lung injury had received SCT treatment (P = .033, Fisher exact test). Multivariate analysis revealed that the concomitant use of corticosteroids might reduce the risk of lung injury (P = .024; odds ratio, 0.055) and that a previous SCT might increase the risk (P = .042; odds ratio, 13.140). We summarized these data from questionnaires for a limited Japanese cohort and therefore do not know the precise incidence of lung injury linked to fatal progression. Thus, future verification concerning this matter is warranted after the approval of bortezomib for use in Japan. Clinicians should be aware of the possibility of severe pulmonary complications associated with bortezomib therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.